BE study Design for Ri­va­rox­aban 20 mg [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-04 13:33 (798 d 19:03 ago) – Posting: # 23103
Views: 2,933

Hello!

The Design for Rivaroxaban 20 mg BE Study stated by US-FDA is as follows:

Single-dose, two-treatment, two-sequence, four-period, fully replicate crossover

Is it possible to go with Single-dose, two-treatment, two-sequence, two-period crossover study design?

Thank You!


Edit: Category changed; see also this post #1. Guidance linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,221 posts in 4,877 threads, 1,656 registered users;
42 visitors (1 registered, 41 guests [including 4 identified bots]).
Forum time: 08:36 CEST (Europe/Vienna)

Explanations exist; they have existed for all time;
there is always an easy solution to every human problem –
neat, plausible and wrong.    H. L. Mencken

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5